Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-1-
ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS
This invention relates to a new use of alpha-2-delta ligands and their
pharmaceutically
acceptable derivatives. In particular it relates to a new use of gabapentin
and pregabalin.
Lower urinary tract symptoms (LUTS) comprise three groups of symptoms, which
are
irritative, obstructive and post micturition symptoms. Irritative symptoms
comprise
urgency, frequency and nocturia, which can be associated with: overactive
bladder (OAB)
and benign prostatic hyperplasia (BPH).
Over Active Bladder (OAB) is defined as urgency, with or without urge
incontinence,
usually with frequency and nocturia [Abrams et al., Neurourology and
Urodynamics
21:167-178 (2002)]. Prevalence of OAB in men and women is similar, with
approximately
16% of the population of the USA suffering from the condition [Stewart et al,
Prevalence of
Overactive Bladder in the United States: Results from the NOBLE Program;
Abstract
Presented at the 2nd International Consultation on Incontinence, July 2001,
Paris, France].
The terms OAB. Wet and OAB Dry describe OAB patients with or without urinary
incontinence respectively. Until recently, the cardinal symptom of OAB was
believed to be
urinary incontinence. However, with the advent of the new terms this is
clearly not
meaningful for the large number of sufferers who are not incontinent (i.e. OAB
Dry
patients). Thus, a recent study from Liberman et al [Health Related Quality of
Life Among
Adults with Symptoms of Overactive Bladder: Results From A US Community-Based
Survey; Urology 57(6), 1044-1050, 2001] examined the impact of all OAB
symptoms on
the quality of life of a community-based sample of the US population. This
study
demonstrated that individuals suffering from OAB without any demonstrable loss
of urine
have an impaired quality of life when compared with controls.
BPH is a chronically progressive disease that can lead to complications such
as acute
urinary retention, recurrent urinary tract infections, bladder stones and
renal dysfunction.
The prevalence and average severity of LUTS associated with BPH in men
increases with
age.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-2-
BPH leads to an increase in prostate volume, creating urethral and bladder
outflow
obstruction as well as secondary changes in bladder function. The effects of
this are
manifested by both storage (irritative) and voiding (obstructive) symptoms.
Alpha-2-delta ligands have been described for a number of indications. The
best known
alpha-2-delta ligand, gabapentin (I), known as Neurontin , 1-(aminomethyl)-
cyclohexylacetic acid, was first described in the patent literature in the
patent family
comprising US4024175.
H2N COOH
(I)
The compound is approved for the treatment of epilepsy and neuropathic pain.
A second alpha-2-delta ligand, pregabalin (II), (S)-(+)-4-amino-3-(2-
methylpropyl)butanoic
acid, is described in European patent application publication number EP641330
as an
anti-convulsant treatment useful in the treatment of epilepsy and in EP0934061
for the
treatment of pain.
O
OH
NH2
(I I)
More recently, International Patent Publication Number WO 02/085839, describes
alpha-
2-delta ligands of the following formulae, for use in the treatment of a
number of
indications, including pain:
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-3-
HOC , H2 HO2C `1 NH2 HO2 C NH2 HO2 C NH2
R1R2 R1 R2
R1 R2 R1R2
(III) (IV) (V) (VI)
Z
HO2C NH HO2C NHZ HO 2C NH 2 HO 2C NH
-R1 R1 {_R1 R1
R2 R2 R2 R2
(VII) (VIII) (IX) (X)
H2N H2N H2NNI H2N
H02C~s :0 H02C HO2C"'jj- j HO2C
(XI) (XII) (XIII) (XIV)
HO2C NH2
HO2C NH2 HO2C NH2 HO2C N H2 HO2C NH2
R1,,,, ooR2 R1,,,, ,,,=R2
RI 'R2 R1 R2
R1 R2
(XV) (XVI) (XVII) (XVIII) (XIX)
H2N H2N H2N\ H2N\
HO2C HO2C HOZC = HOZC \_~EI1{w`,JII
114,11 . ,,,)
XX XXI XXII XXI I I
H2N H2N H2N, H2N\
HO
2 C HOC
H02C`,.= H02C ~^\
D
XXIV XXV XXVI XXVI I
wherein R1 and R2 are each independently selected from H, straight or branched
alkyl of
1-6 carbon atoms, cycloalkyl of from 3-6 carbon atoms, phenyl and benzyl,
subject to the
proviso that, except in the case of a tricyclooctane compound of formula
(XVIII), R' and R2
are not simultaneously hydrogen.
Further examples of alpha-2-delta ligands are the compounds depicted below:
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-4-
F
P-Cl F F
O F
O O O O
H OH H OH H OH H OH
XXVIII XXIX XXX XXXI
Useful cyclic alpha-2-delta ligands of the present invention are illustrated
by the following
formula (I):
NH2 X
R R4a
R la R4)
R2 R3a
Rea R3
wherein X is a carboxylic acid or carboxylic acid bioisostere;
n is 0, 1 or 2; and
R1, R'a, R2, R2a, R3, R3a, R4 and R4a are independently selected from H and Cj-
C6 alkyl, or
R1 and R2 or R2 and R3 are taken together to form a C3-C7 cycloalkyl ring,
which is
optionally substituted with one or two substituents selected from C1-C6 alkyl,
or a
pharmaceutically acceptable salt thereof.
In formula (I), suitably, R1, R'a, R2a, R3a, R4 and R4a are H and R2 and R3
are
independently selected from H and methyl, or R'a, R2a, R3a and R4a are H and
R1 and R2
or R2 and R3 are taken together to form a C3-C7 cycloalkyl ring, which is
optionally
substituted with one or two methyl substituents. A suitable carboxylic acid
bioisostere is
selected from tetrazolyl and oxadiazolonyl. X is preferably a carboxylic acid.
In formula (I), preferably, R1, R'a, R2a, R3a, R4 and R4a are H and R2 and R3
are
independently selected from H and methyl, or R", R2a, R3a and R4a are H and R1
and R2
or R2 and R3 are taken together to form a C4-C5 cycloalkyl ring, or, when n is
0, R1, R'a,
R2a, R3a, R4 and R4a are H and R2 and R3 form a cyclopentyl ring, or, when n
is 1, R', R'a,
R2a, R3a, R4 and R4a are H and R2 and R3 are both methyl or R1, R'a, R2a, WE,
R4 and R4a
are H and R2 and R3 form a cyclobutyl ring, or, when n is 2, R1, R'a, R2, R2a,
R3, R3a, R4
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-5-
and R4a are H, or, n is 0, R1, R'a, Rea, R3a, R4 and R4a are H and R2 and R3
form a
cyclopentyl ring.
Useful acyclic alpha-2-delta ligands of the present invention are illustrated
by the following
formula (II):
R4 R5
R3
H2N R6 R2
HOOC (II)
wherein:
n is 0 or 1, R1 is hydrogen or (C,-C6)alkyl; R2 is hydrogen or (C1-C6)alkyl;
R3 is
hydrogen or (C,-C6)alkyl; R4 is hydrogen or (C,-C6)alkyl; R5 is hydrogen or
(Cj-C6)alkyl
and R2 is hydrogen or (Ci-C6)alkyl, or a pharmaceutically acceptable salt
thereof.
According to formula (II), suitably R1 is CI-C6 alkyl, R2 is methyl, R3 - R6
are hydrogen and
n is 0 or 1. More suitably R1 is methyl, ethyl, n-propyl or n-butyl, R2 is
methyl, R3 - R6 are
hydrogen and n is 0 or 1. When R2 is methyl, R3 - R6 are hydrogen and n is 0,
R1 is
suitably ethyl, n-propyl or n-butyl. When R2 is methyl, R3 - R6 are hydrogen
and n is 1, R1
is suitably methyl or n-propyl. Compounds of formula (II) are suitably in the
33,5R
configuration.
Examples of alpha-2-delta ligands for use with the present invention are those
compounds
generally or specifically disclosed in US4024175, particularly gabapentin,
EP641330,
particularly pregabalin, US5563175, W09733858, W09733859, W09931057,
W09931074, W097291 01, W002085839, particularly [(1R,5R,6S)-6-
(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, W09931075, particularly 3-(1-
Aminomethyl-cyclohexyl methyl)- 4H-[1,2,4]oxadiazol-5-one and C-[1-(1H-
Tetrazol-5-
ylmethyl)-cycloheptyl]-methylamine, W09921824, particularly (3S,4S)-(1-
Aminomethyl-
3,4-dimethyl-cyclopentyl)-acetic acid, WO0190052, WO0128978, particularly
(1a,3a,5a)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, EP0641330,
W09817627, W00076958, particularly (3S,5R)-3-aminomethyl-5-methyl-octanoic
acid,
PCT/IB03/00976, particularly (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-
3-amino-5-methyl-nonanoic acid and (3S,5R)-3-Amino-5-methyl-octanoic acid,
EP1178034, EP1201240, W09931074, W003000642, W00222568, W00230871,
CA 02509605 2009-06-30
69387-506
-6-
W00230881, W002100392, W002100347, W00242414, W00232736 and W00228881
or pharmaceutically acceptable salts thereof.
Preferred alpha-2-delta ligands of the present invention include: gabapentin,
pregabalin,
[(1 R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yljacetic acid, 3-(1-
Aminomethyl-
cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1 H-Tetrazol-5-ylmethyl)-
cycloheptyl]-
methylamine, (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic . acid,
(1a,3a,5a)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-
Aminomethyl-
5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-
amino-
5-methyl-nonanoic acid and (3S,5R)-3-Amino-5-methyl-octanoic acid, or
pharmaceutically
acceptable salts thereof. Particularly preferred alpha-2-delta ligands of the
present
invention are selected from gabapentin, pregabalin and (1 a,3a,5a)(3-amino-
methyl-
bicyclo[3.2.0]hept-3-yl)-acetic acid, or pharmaceutically acceptable salts
thereof.
WO 00/01135 describes the use of analogs of glutamic acid and gamma-
aminobutyric
acid as being useful in treating incontinence.
Surprisingly, it has been found that alpha-2-delta ligands, such as those
described above,
are useful in the treatment of LOTS, other than urinary incontinence,
associated with OAB
and/or BPH. More particularly, it has been found that alpha-2-delta ligands
are useful in
treating the frequency aspect of LUTS associated with OAB and/or BPH. This
finding is
surprising because it could not have been predicted that a compound known to
be useful
in the treatment of urinary incontinence (i.e. the unwanted and often
unconscious leaking
of urine due to problems with muscular control) would be able to reduce the
frequency
symptoms endured by sufferers of OAB and BPH.
CA 02509605 2009-06-30
69387-506
- 6a -
Thus, in accordance with the present invention there is provided the
use of an alpha-2-delta ligand, or a pharmaceutically acceptable salt or
solvate
thereof, for the treatment of LUTS, other than urinary incontinence,
associated
with OAB and/or BPH.
In a further aspect, there is provided the use of an alpha-2-delta
ligand, or a pharmaceutically acceptable salt or solvate thereof, for the
manufacture of a medicament for the treatment of LUTS, other than urinary
incontinence, associated with OAB and/or BPH.
Preferably, the LUTS is frequency. Preferably, the LUTS is
associated with BPH. Preferably, when the LUTS is associated with OAB, the
OAB is OAB Dry.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-7-
Preferably the alpha-2-delta-1-ligand is selected from:
HZN-6COOH 0
OH
NH2
(I) (H)
HOZC NH 2 HOZC j H2 HO2 C NH2 HO2 C NH2
R11 o1R2 R1 R2
R1 R2 RI R2
(III) (IV) (V) (VI)
HO2C NH HO2C NH HO2C NHZ HO2C NH
a
R1 R1 R1
R2 R2 R2 R2
(VII) (VIII) (IX) (X)
H2N H2N H2N H2N
HO2C~, HO2C~,.= HO2HO2C
(XI) (XII) (XIII) (XIV)
HOZC NH2
HOZC NH2 HO2C NH2 HO2C `1 H2 HO 2C l H2
R1,,,, ,oR2 RI I'll -R2
R1 R2 R1 R2 n
R1 R2
(XV) (XVI) (XVII) (XVIII) (XIX)
H2N H2N H2N, H2N
HO2C HO2C HO2C HO2C
XX XXI XXII XXIII
H2N H2N H2N, H2N\
HO2C ;
O2C HO2C` =;==`9 HO2C
D H
to
XXIV XXV XXVI XXVI I
2
N
H N H N~ O H2
N `^
2 2
JT
HNC HN NH (OH HO2C
z
0
(XXVIII) (XXIX) (XXX) (XXXI)
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-8-
0 OH
NHa
HEN
HO2C
(XXXII) (XXXIII)
or a pharmaceutically acceptable salt or solvate thereof, wherein R1 and R2
are each
independently selected from H, straight or branched alkyl of 1-6 carbon atoms,
cycloalkyl
of from 3-6 carbon atoms, phenyl and benzyl, subject to the proviso that,
except in the
case of a tricyclooctane compound of formula (XVIII), R1 and R2 are not
simultaneously
hydrogen; or it is selected from
F
CI F F
0,,
O F
O O O 0
H OH H OH H OH OH
XXXIV XXXV XXXVI XXXVII
or a pharmaceutically acceptable sat or solvate thereof.
More preferably the alpha-2-delta ligand is gabapentin (I), pregabalin (II) or
(1a,3a,5(X)(3-
amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid (III')
HO2C NH2
H~'õ H
(III')
or a pharmaceutically acceptable salt or solvate thereof.
The alpha-2-delta ligand, or pharmaceutically acceptable derivative thereof,
can be
administered alone or in any convenient pharmaceutical presentation. Oral
administration
is preferred. In the present indication, a suitable dosage of the alpha-2-
delta ligand, or of
the active moiety in a pharmaceutically acceptable derivative thereof, is from
about 5 to 50
mg/kg of body weight, and preferably about 0.1 to 200 mg/kg.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-9-
The invention further provides a method of treating LUTS, other than urinary
incontinence,
associated with OAB and/or BPH comprising administering an alpha-2-delta
ligand, or
pharmaceutically acceptable salt or solvate thereof, to a patient in need of
such treatment.
Alpha-2-delta ligands, particularly the compounds described above, may be used
in
combination with other compounds. For example, they may be used in combination
with
a1-Adrenergic antagonists.
Thus, a further aspect of the present invention is the use of a combination of
an alpha-2-
delta ligand and an al-Adrenergic antagonist, or pharmaceutically acceptable
salts or
solvates thereof, for the manufacture of a medicament for the treatment of
LUTS,
associated with OAB and/or BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and an a1-
Adrenergic antagonist, or pharmaceutically acceptable salts or solvates
thereof, as a
combined preparation for simultaneous, separate or sequential use in the
treatment of
LUTS associated with OAB and/or BPH.
Preferably, the LUTS is other than urinary incontinence. More preferably, the
LUTS is
frequency. Preferably the LUTS is associated with BPH. Preferably, when the
LUTS is
associated with OAB, it is OAB dry.
a,-Adrenergic receptor antagonists useful for combining with alpha-2-delta
ligands
include, but are not limited to,
(i) terazosin (US Paiznt No. 4,026,894);
(ii) doxazosin (US Patent No. 4,188,390);
(iii) prazosin (US Patent No. 3,511,836);
(iv) bunazosin (US Patent No. 3,920,636);
(v) alfuzosin (US Patent No. 4,315,007);
(vi) naftopidil (US Patent No. 3,997,666);
(vii) tamsulosin (US Patent No. 4,703,063);
(viii) silodosin (US Patent No. 5,387,603); or
(ix) the compounds disclosed in International Patent Application Publication
No.
WO 98/30560 (particularly example 19 and its mesylate salt).
CA 02509605 2009-06-30
69387-506
-10-
Alternatively, alpha-2-delta ligands may be used in combination with a
compound which
shows NRI and/or SRI activity. Thus a further aspect of the present invention
is the use of
a combination of an alpha-2-delta ligand and a compound showing NRI and/or SRI
activity, or pharmaceutically acceptable salts or solvates thereof, for the
manufacture of a
medicament for the treatment of LUTS associated with OAB and/or BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and a compound
showing NRI and/or SRI activity, or pharmaceutically acceptable salts or
solvates thereof,
as a combined preparation for simultaneous, separate or sequential use in the
treatment
of LUTS associated with OAB and/or BPH.
Preferably, the LUTS is other than urinary incontinence. More preferably, the
LUTS is
frequency. Preferably the LUTS is associated with BPH. Preferably, when the
LUTS is
associated with.OAB, the OAB is OAB dry.
Compounds having NRI and/or SRI activity which are useful for use in the
present
invention include, but are not limited to, the compounds below:
(i) Fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, vanlafaxine,
nefazodone, trazodone, duloxetine and reboxetine (in both racemic and
enantiomerically pure forms, e.g. S,S-reboxetine); and
(ii) The compounds disclosed in European Patent Publication No's 1220831
and 1154984, U.S. patent No. 4,018,830, International Patent Publication
No. WO 97/17325, U.S. Patent Nos. 5,190,965, 5,430,063, and 4,161,529.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-11-
Alternatively, alpha-2-delta ligands may be used in combination with a HMG Co-
A
Reductase inhibitor. Thus a further aspect of the present invention is the use
of a
combination of an alpha-2-delta ligand and a HMG Co-A Reductase inhibitor, or
a
pharmaceutically acceptable salt or solvate thereof, for the manufacture of a
medicament
for the treatment of LUTS associated with OAB and/or BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and a HMG Co-
A Reductase inhibitor, or a pharmaceutically acceptable salt or solvate
thereof, as a
combined preparation for simultaneous, separate or sequential use in the
treatment of
LUTS associated with OAB and/or BPH.
Preferably, the LUTS is other than urinary incontinence. More preferably, the
LUTS is
frequency. Preferably the LUTS is associated with BPH. Preferably, when the
LUTS is
associated with OAB, the OAB is OAB dry.
HMG Co-A Reductase inhibitors useful for use in the present invention include,
but are not
limited to, the compounds below:
(i) Fluvastatin sodium, [R*, S*, -(E)]-( )-7-[3-(4-fluorophenyl)-1-(1-
methylethyl)-H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, monosodium
salt;
(ii) Cerivastatin sodium, [S-[R*, S*-(E)]-7-[4-(4-fluorophenyl)-5-
methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-
heptenoate;
(iii) Atorvastatin calcium, [R-(R*, R*)]-2-(4-fluorophenyl)-beta, delta-
dihydroxy-
5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1 H-pyrrole-1-
heptanoic acid, calcium salt (2:1) trihydrate;
(iv) Lovastatin, {S-[1-alpha(R*), 3-alpha, 7-beta, 8-beta (2S*, 4S*)88a beta]}-
1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-
pyran-2-yl)ethyl]-1-naphthalenyl-2-methylbutanoate;
(v) Pravastatin sodium, 1-naphthalene-heptanoic acid, 1,2,6,7,8,8a-
hexahydro-beta, delta, 6-trihyd roxy-2-methyl-8-(2-methyl- 1 -oxobutoxy)-,
monosodium salt, {1 S-[1 alpha(betas*, deltas*), 2 alpha, 6 alpha, 8
beta(R*), 8a alpha]}; and
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-12-
(vi) Simvastatin, butanoic acid,2,2-dimethyl-1,2,3,7,8,8a-hexahydro-3,7-
dimethyl-8-[2-(tetrahydro-4-hyd roxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-
naphthalenyl ester, {1 S-[1 alpha,3alpha,7beta,8beta(2S*,4S*),-8 a beta]}
Alternatively, alpha-2-delta ligands may be used in combination with PDEV
inhibitors.
Thus a further aspect of the present invention is the use of a combination of
an alpha-2-
delta ligand and a PDEV inhibitor, or pharmaceutically acceptable salts or
solvates thereof,
for the manufacture of a medicament for the treatment of LUTS associated with
OAB
and/or BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and a PDEV
inhibitor, or pharmaceutically acceptable salts or solvates thereof, as a
combined
preparation for simultaneous, separate or sequential use in the treatment of
LUTS
associated with OAB and/or BPH.
Preferably, the LUTS is other than urinary incontinence. More preferably, the
LUTS is
frequency. Preferably the LUTS is associated with BPH. Preferably, when the
LUIS is
associated with OAB, the OAB is OAB dry.
PDEV inhibitors useful for combining with alpha-2-delta ligands include, but
are not limited
to:
(i) The PDE5 inhibitors mentioned in International Patent Application
publication
nos. W003/000691; W002/64590; W002/28865; W002/28859; W002/38563;
W002/36593; W002/28858; W002/00657; W002/00656; W002/10166;
W002/00658; W001/94347; W001/94345; W000/15639 and W000/15228;
(ii) The PDE5 inhibitors mentioned in US Patents 6,143,746; 6,143,747 and
6,043,252;
(iii) the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0463756; the
pyrazolo
[4,3-d]pyrimidin-7-ones disclosed in EP-A-0526004; the pyrazolo [4,3-
d]pyrimidin-7-ones disclosed in published international patent application WO
93/06104; the isomeric pyrazolo [3,4-d]pyrimidin-4-ones disclosed in published
international patent application WO 93/07149; the quinazolin-4-ones disclosed
in published international patent application WO 93/12095; the pyrido [3,2-
d]pyrimidin-4-ones disclosed in published international patent application WO
94/05661; the purin-6-ones disclosed in published international patent
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-13-
application WO 94/00453; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in
published international patent application WO 98/49166; the pyrazolo [4,3-
d]pyrimidin-7-ones disclosed in published international patent application WO
99/54333; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-0995751; the
pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent
application WO 00/24745; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-
A-0995750; the hexahydropyrazino [2',1':6,1]pyrido [3,4-b]indole-1,4-diones
disclosed in published international application W095/19978; the pyrazolo [4,3-
d]pyrimidin-4-ones disclosed in W000/27848; the imidazo[5,1-fJ[1,2,4]triazin-
ones disclosed in EP-A-1092719 and in published international application WO
99/24433 and the bicyclic compounds disclosed in published international
application WO 93/07124; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in
published international application WO 01/27112; the pyrazolo [4,3-d]pyrimidin-
7-ones disclosed in published international application WO 01/27113; the
compounds disclosed in EP-A-1092718 and the compounds disclosed in EP-A-
1092719; the tricyclic compounds disclosed in EP-A-1241170; the alkyl
sulphone compounds disclosed in published international application WO
02/074774; the compounds disclosed in published international application WO
02/072586; the compounds disclosed in published international application WO
02/079203 and the compounds disclosed in WO 02/074312.
(iv) Preferably 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-
methyl-3-
n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil, e.g. as
sold
as Viagra ) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine
(see EPA-0463756);5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-
propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EPA-0526004);3-
ethyl-5-[5-(4-ethylpiperazin-1 -ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-
yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see W098/49166);3-
ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-
(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one(see
W099/54333); (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-
1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-
d]pyrimidin-7-one, also known as 3-ethyl-5-{5-[4-ethylpiperazin-1-ylsulphonyl]-
2-([(1 R)-2-methoxy-1 -methylethyl]oxy)pyridin-3-yl}-2-methyl-2,6-dihydro-7H-
pyrazolo[4,3-d] pyrimidin-7-one (see W099/54333);5-[2-ethoxy-5-(4-
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-14-
ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6-ethoxy-5-[3-
ethyl-6,7-d ihyd ro-2-(2-methoxyethyl)-7-oxo-2 H -pyrazolo[4,3-d] pyrimid in-5-
yl]-3-
pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8);5-[2-iso-
Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-
methylpiperidin-4-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one(see WO
01/27113, Example 15);5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-
yl]-3-ethyl-2-phenyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO
01/27113, Example 66);5-(5-Acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-
isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO
01/27112, Example 124); 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-
azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112,
Example 132); (6R, 1 2aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-
methylenedioxyphenyl)pyrazino[2',1':6,1 ]pyrido[3,4-b]indole-1,4-dione
(tadalafil,
IC-351, Cialis ), i.e. the compound of examples 78 and 95 of published
international application W095/19978, as well as the compound of examples 1,
3, 7 and 8; 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-
methyl-
7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil, LEVITRA ) also
known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-
yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples
20, 19, 337 and 336 of published international application W099/24433;the
compound of example 11 of published international application W093/07124
(EISAI); compounds 3 and 14 from Rotella D P, J. Med. Chem., 2000, 43,
1257; 4-(4-chlorobenzyl)amino-6,7,8-trimethoxyquinazoline; N-[[3-(4,7-dihydro-
1-methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4-
propxyphenyl]sulfonyl]-1-methyl2-pyrrolidinepropanamide ["DA-8159" (Example
68 of W000/27848)]; and 7,8-dihydro-8-oxo-6-[2-propoxyphenyl]-1H-
imidazo[4,5-g]quinazoline and 1-[3-[1-[(4-fluorophenyl)methyl]-7,8-dihydro-8-
oxo-1 H-imidazo[4,5-g]quinazolin-6-yl]-4-propoxyphenyl]carboxamide.
(v) 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)-propoxy]-
3(2H)pyridazi none; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amiono]-6-chloro-2-
quinozolinyl]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis-
5,6a,7,9,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl-
cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5-
methyl-
3,4,5,6a,7,8,9,9a- octahydrocyclopent[4,5]-imidazo[2,1-b]purin-4-one; 3-acetyl-
CA 02509605 2009-06-30
69387-506
-15-
1-(2-chlorobenzyl)-2-propylindole-6- carboxylate; 3-acetyl-1-(2-chlorobenzyl)-
2-
propylindole-6-carboxylate; 4-bromo-5-(3-pyridylmethylamino)-6-(3-(4-
chlorophenyl) propoxy)-3- (2H)pyridazinone; I-methyl-5(5-morpholinoacetyl-2-n-
propoxyphenyl)-3-n-propyl-1,6-dihydro- 7H-pyrazolo(4,3-d)pyrimidin-7-one; 1-
[4-[(1,3-benzodioxol-5-ylmethyl)arnino]-6-chloro-2- quinazolinyl]-4-
piperidinecarboxylic acid, monosodium salt; Pharmaprojects No. 4516 (Glaxo
Wellcome); Pharmaprojects No. 5051 (Bayer); Pharmaprojects No. 5064
(Kyowa Hakko; see WO 96/26940); Pharmaprojects No. 5069 (Schering
Plough); GF-196960 (Glaxo Wellcome); E-8010 and E-4010 (Eisai); Bay-38-
3045 & 38-9456 (Bayer); FR229934 and FR226807 (Fujisawa); and Sch-
51866.
Preferably the PDEV inhibitor is selected from sildenafil, tadalafil,
vardenafil, DA-8159 and
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-
methoxyethyl]-2,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.
Most preferably the PDE5 inhibitor is sildenafil and pharmaceutically
acceptable salts
thereof. Sildenafil citrate is a preferred salt.
Alternatively, alpha-2-delta ligands may be combined with muscarinic
antagonists. Thus,
a further aspect of the present invention is the use of a combination of an
alpha-2-delta
ligand and a muscarinic antagonist, or pharmaceutically acceptable salts or
solvates
thereof, for the manufacture of a medicament for the treatment of LUTS,
associated with
OAB and/or BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and a
muscarinic antagonist, or pharmaceutically acceptable salts or solvates
thereof, as a
combined preparation for simultaneous, separate or sequential use in the
treatment of
LUTS associated with OAB and/or BPH.
CA 02509605 2009-06-30
69387-506
-16-
Preferably, the LUTS is other than urinary incontinence. More Preferably, the
LUTS is
frequency. Preferably, the LUTS is associated with BPH_ Preferably, when the
LUTS is
associated with OAB, the OAB is OAB dry.
The muscarinic antagonist can be selective for M3 receptors or it can be non-
selective,
exhibiting antagonism at MI, M2 and M3. Antagonists selective for the M3
receptor are
preferred.
Muscarinic antagonists useful for combining with alpha-2-delta ligands
include, but are not
limited to:
(i) Atropine, fluvoxate, hyoscine, oxybutynin, tolterodine and the compounds
disclosed in International Patent Publication No. WO 89/06644, propantheline,
propiverine, trospium, and the compounds disclosed in International Patent
Publication No. WO 98/05641, along with the pharmaceutically acceptable salts
thereof..
(ii) Especially preferred are darifenacin, oxybutynin, tolterodine and the
compounds
disclosed in International Patent Publication No. WO 89106644, and the
compounds disclosed in International Patent Publication No. WO 98/05641, along
with the pharmaceutically acceptable salts thereof.
In particular tolterodine is of interest.
Alternatively, alpha-2-delta ligands may be combined with cyclooxygenase
inhibitors.
Thus, a further aspect of the present invention is the use of a combination of
an alpha-2-
delta ligand and a COX inhibitor, or pharmaceutically acceptable salts or
solvates thereof,
for the manufacture of a medicament for the treatment of LUTS, associated with
OAB
and/or BPH.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-17-
Still further there is provided a product containing an alpha-2-delta ligand
and a COX
inhibitor as a combined preparation for simultaneous, separate or sequential
use in the
treatment of LUTS associated with OAB and/or BPH.
Preferably, the LUTS is other than urinary incontinence. More preferably, the
LUTS is
frequency. Preferably, the LUTS is associated with BPH. Preferably, when the
LUTS is
associated with OAB it is OAB dry. Preferably the COX inhibitor is a COX2
inhibitor.
COX inhibitors useful for combining with alpha-2-delta ligands include, but
are not limited
to:
(i) ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen,
ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen,
miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen,
bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, diclofenac,
fenclofenec, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin,
acetyl salicylic acid, indometacin, piroxicam, tenoxicam, nabumetone,
ketorolac, azapropazone, mefenamic acid, tolfenamic- acid, diflunisal,
podophyllotoxin derivatives, acemetacin, droxicam, floctafenine,
oxyphenbutazone, phenylbutazone, proglumetacin, acemetacin, fentiazac,
clidanac, oxipinac, mefenamic acid, meclofenamic acid, flufenamic acid,
niflumic acid, flufenisal, sudoxicam, etodolac, piprofen, salicylic acid,
choline
magnesium trisalicylate, salicylate, benorylate, fentiazac, clopinac,
feprazone,
isoxicam and 2-fluoro-a-methyl[1,1'-biphenyl]-4-acetic acid, 4-(nitrooxy)butyl
ester (See Wenk, et al., Europ. J. Pharmacol. 453:319-324 (2002));
(ii) meloxicam, (CAS registry number 71125-38-7; described in U.S. Patent No.
4,233,299), or a pharmaceutically acceptable salt or prodrug thereof;
(iii) Substituted benzopyran derivatives that are described in U.S. Patent No.
6,271,253. Also benzopyran derivatives described in U.S. Patent Nos.
6,034,256 and 6,077,850 along with International Publication No's WO
98/47890 and WO 00/23433;
(iv) Chromene COX2 selective inhibitors described in U.S. Patent No. 6,077,850
and U.S. Patent No. 6,034,256;
(v) The compounds described in International Patent Application Publication
No's
WO 95/30656, WO 95/30652, WO 96/38418 and WO 96/38442, and the
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
- 18-
compounds described in European Patent Application Publication No. 799823,
along with the pharmaceutically acceptable derivatives thereof;
(vi) celecoxib (US Patent No. 5,466,823), valdecoxib (US Patent No.
5,633,272),
deracoxib (US Patent No. 5,521,207), rofecoxib (US Patent No. 5,474,995),
etoricoxib (International Patent Application Publication No. WO 98/03484),
JTE-522 (Japanese Patent Application Publication No. 9052882), or a
pharmaceutically acceptable salt or prodrug thereof;
(vii) Parecoxib (described in U.S. Patent No. 5,932,598), which is a
therapeutically
effective prodrug of the tricyclic Cox-2 selective inhibitor valdecoxib
(described
in U.S. Patent No. 5,633,272), in particular sodium parecoxib;
(viii) ABT-963 (described in International Patent Application Publication No.
WO
00/24719)
(ix) Nimesulide (described in U.S. Patent No. 3,840,597), flosulide (discussed
in J.
Carter, Exp.Opin.Ther.Patents, 8(1), 21-29 (1997)), NS-398 (disclosed in U.S.
Patent No. 4,885,367), SD 8381 (described in U.S. Patent No. 6,034,256),
BMS-347070 (described in U.S. Patent No. 6,180,651), S-2474 (described in
European Patent Publication No. 595546) and MK-966 (described in U.S.
Patent No. 5,968,974);
(x) The compounds and pharmaceutically acceptable derivatives described in
U.S.
Patent No. 6,395,724, U.S. Patent No. 6,077,868, U.S. Patent No. 5,994,381,
U.S. Patent No. 6,362,209, U.S. Patent No. 6,080,876, U.S. Patent No
6,133,292, U.S. Patent No. 6, 369,275, U.S. Patent No. 6,127,545, U.S. Patent
No. 6,130,334, U.S. Patent No. 6,204,387, U.S. Patent No. 6,071,936, U.S.
Patent No. 6,001,843, U.S. Patent No. 6,040,450, International Patent
Application Publication No WO 96/03392, International Patent Application
Publication No WO 96/24585, U.S. Patent No. 6,340,694, U.S. Patent No.
6,376,519, U.S. Patent No. 6,153,787, U.S. Patent No. 6,046,217, U.S. Patent
No. 6,329,421, U.S. Patent No. 6,239,137, U.S. Patent No. 6,136,831, U.S.
Patent No. 6,297,282, U.S. Patent No. 6,239,173, U.S. Patent No. 6,303,628,
U.S. Patent No. 6,310,079, U.S. Patent No. 6,300,363, U.S. Patent No.
6,077,869, U.S. Patent No. 6,140,515, U.S. Patent No. 5,994,379, U.S. Patent
No. 6,028,202, U.S. Patent No. 6,040,320, U.S. Patent No. 6,083,969, U.S.
Patent No 6,306,890, U.S. Patent No. 6,307,047, U.S. Patent No. 6,004,948,
U.S. Patent No. 6,169,188, U.S. Patent No. 6,020,343, U.S. Patent No.
5,981,576, U.S. Patent No. 6,222,048, U.S. Patent No. 6,057,319, U.S. Patent
CA 02509605 2009-06-30
69387-506
-19-
No. 6,046,236, U.S. Patent No. 6,002,014, U.S. Patent No. 5,945,539, U.S.
Patent No. 6,359,182, International Patent Application Publication No. WO
97/13755, International Patent Application Publication No. WO 96/25928,
International Patent Application Publication No. WO 96/374679, International
Patent Application Publication No. WO 95/15316, International Patent
Application Publication No. WO 95/15315, International Patent Application
Publication No. WO 96/03385, International Patent Application No. WO
95/00501, International Patent Application No. WO 94/15932, International
Patent Application Publication No. WO 95/00501, International Patent
Application Publication No. WO 94/27980, International Patent Application
Publication No. WO 96/25405, International Patent Application Publication No.
WO 96/03388, International Patent Application Publication No. WO 96/03387,
U.S. Patent No. 5,344,991, International Patent Application Publication No.
WO 95/00501, International Patent Application Publication No. WO 96/16934,
International Patent Application Publication No. WO 96/03392, International
Patent Application Publication No. WO 96/09304, International Patent
Application Publication No. WO 98/47890, and International Patent Application
Publication No. WO 00/24719.
When treating BPH, alpha-2-delta Iigands may be combined with a compound that
attenuates the growth of the prostate gland. For example, a formulation is
envisaged that
combines an alpha-2-delta ligand with a human 5-a reductase inhibitory
compound [see
International Patent Application WO 95/28397].
Thus, a further aspect of the present invention is the use of a combination of
an alpha-2-
delta ligand and a human 5- a reductase inhibitory compound, or
pharmaceutically
acceptable salts or solvates thereof, for the manufacture of a medicament for
the
treatment of LUTS, other than urinary incontinence, associated with BPH.
Still further there is provided a product containing an alpha-2-delta ligand
and a human 5-
a reductase inhibitory compound, or pharmaceutically acceptable salts or
solvates thereof,
CA 02509605 2009-06-30
69387-506
-20-
as a combined preparation for simultaneous, separate or sequential use in the
treatment
of LUTS, other than urinary incontinence, associated with BPH.
Preferably the LUTS is frequency.
In yet another aspect, the present invention provides a commercial package
comprising
an alpha-2-delta ligand, or a pharmaceutically acceptable salt or solvate
thereof,
together with instructions for treating any of the conditions described
herein.
The use of the compounds and combinations described herein may have the
advantage
that higher potency, longer duration of action, fewer side effects, improved
selectivity, or
other more useful properties are achieved compared to the uses of the prior
art when
treating LUTS associated with OAB and/or BPH, particularly when the LUTS is
frequency.
The compounds of the present invention are prepared by methods well known to
those
skilled in the art. Specifically, the patents, patent applications and
publications, mentioned
hereinabove, each of which is hereby incorporated herein by reference,
exemplify
compounds which can be used in combinations, pharmaceutical compositions,
methods
and kits in accordance with the present inventions, and refer to methods of
preparing
those compounds.
Pharmaceutically acceptable salts of the compounds suitable for use in the
invention
include the acid addition and base salts thereof.
Suitable acid addition salts are formed from acids which form non-toxic salts.
Examples
include th e acetate, aspartate, benzoate, besylate, bicarbonate/carbonate,
bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate,
fumarate,
gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate,
hydrochloride/chloride, hydrobromide/bromide, hydroiodiderodide, isethionate,
lactate,
malate, maleate, malonate, mesylate. methylsulphate, naphthylate, 2-napsylate,
nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen
phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate,
tosylate and
trifluoroacetate salts.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-21-
Suitable base salts are formed from bases which form non-toxic salts. Examples
include
the aluminium, arginine, benzathine, calcium, choline, diethylamine,
diolamine, glycine,
lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and
zinc
salts.
For a review on suitable salts, see "Handbook of Pharmaceutical Salts:
Properties,
Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
A pharmaceutically acceptable salt of a compound suitable for use in the
present
invention may be readily prepared by mixing together solutions of the compound
and the
desired acid or base, as appropriate. The salt may precipitate from solution
and be
collected by filtration or may be recovered by evaporation of the solvent. The
degree of
ionisation in the salt may vary from completely ionised to almost non-ionised.
The compounds suitable for use in the present invention may exist in both
unsolvated and
solvated forms. The term `solvate' is used herein to describe a molecular
complex
comprising the compound of the invention and one or. more pharmaceutically
acceptable
solvent molecules, for example, ethanol. The term `hydrate' is employed when
said
solvent is water.
Included within the scope of the invention are complexes such as clathrates,
drug-host
inclusion complexes wherein, in contrast to the aforementioned solvates, the
drug and
host are present in stoichiometric or non-stoichiometric amounts. Also
included are
complexes of the drug containing two or more organic and/or inorganic
components which
may be in stoichiometric or i ion-stoichiometric amounts. The resulting
complexes may be
ionised, partially ionised, or non-ionised. For a review of such complexes,
see J Pharm
Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
Hereinafter all references to compounds suitable for use in the present
invention include
references to salts, solvates and complexes thereof and to solvates and
complexes of
salts thereof.
The compounds suitable for use in the present invention include the compounds
as
hereinbefore defined, polymorphs, prodrugs, and isomers thereof (including
optical,
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-22-
geometric and tautomeric isomers) as hereinafter defined and isotopically-
labelled
compounds.
As stated, the invention includes all polymorphs of the compounds suitable for
use in the
present invention as hereinbefore defined.
Also within the scope of the invention are so-called `prodrugs' of the
compounds suitable
for use in the present invention. Thus certain derivatives of compounds
suitable for use in
the present invention which may have little or no pharmacological activity
themselves can,
when administered into or onto the body, be converted into compounds having
the desired
activity, for example, by hydrolytic cleavage. Such derivatives are referred
to as
`prodrugs'. Further information on the use of prodrugs may be found in `Pro-
drugs as
Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella)
and
`Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E B Roche,
American
Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by
replacing
appropriate functionalities present in the compounds suitable for use in the
present
invention with certain moieties known to those skilled in the art as 'pro-
moieties' as
described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier,
1985).
Some examples of prodrugs in accordance with the invention include:
(i) where the compound contains a carboxylic acid functionality
(-COOH), an ester thereof, for example, replacement of the hydrogen with (C,-
C8)alkyl;
(ii) where the compound contains an alcohol functionality (-OH), an ether
thereof, for
example, replacement of the hydrogen with (C,-C6)alkanoyloxymethyl; and
(iii) where the compound contains a primary or secondary amino functionality (-
NH2 or -
NHR where R # H), an amide thereof, for example, replacement of one or both
hydrogens
with (C,-C1o)alkanoyl.
Further examples of replacement groups in accordance with the foregoing
examples and
examples of other prodrug types may be found in the aforementioned references.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-23-
Finally, certain compounds suitable for use in the present invention may
themselves act as
prodrugs of other compounds suitable for use in the present invention.
Compounds suitable for use in the present invention containing one or more
asymmetric
carbon atoms can exist as two or more stereoisomers. Where a compound contains
an
alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are
possible. Where the
compound contains, for example, a keto or oxime group or an aromatic moiety,
tautomeric
isomerism ('tautomerism') can occur. It follows that a single compound may
exhibit more
than one type of isomerism.
Included within the scope of the present invention are all stereoisomers,
geometric
isomers and tautomeric forms of the compounds suitable for use in the present
invention
as hereinbefore described, including compounds exhibiting more than one type
of
isomerism, and mixtures of one or more thereof. Also included are acid
addition or base
salts wherein the counter-ion is optically active, for example, D-lactate or L-
lysine, or
racemic, for example, DL-tartrate or DL-arginine.
The present invention includes all pharmaceutically acceptable isotopically-
labelled
compounds suitable for use in the present invention as hereinbefore described
wherein
one or more atoms are replaced by atoms having the same atomic number, but an
atomic
mass or mass number different from the atomic mass or mass number usually
found in
nature.
Examples of isotopes suitable for inclusion in the compounds of the invention
include
isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C,
chlorine, such
as 36CI, fluorine, such as 18F, iodine, such as 1231 and 1251, nitrogen, such
as 13N and 15N,
oxygen, such as 150, 170 and 180, phosphorus, such as 32P, and sulphur, such
as 35S.
Pharmaceutically acceptable solvates in accordance with the invention include
those
wherein the solvent of crystallization may be isotopically substituted, e.g.
D20, d6-acetone,
d6-DMSO.
Compounds of the invention intended for pharmaceutical use may be administered
as
crystalline or amorphous products. They may be administered alone or in
combination
with one or more other compounds of the invention or in combination with one
or more
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-24-
other drugs (or as any combination thereof). Generally, they will be
administered as a
formulation in association with one or more pharmaceutically acceptable
excipients. The
term "excipient" is used herein to describe any ingredient other than the
compound(s) of
the invention. The choice of excipient will to a large extent depend on
factors such as the
particular mode of administration, the effect of the excipient on solubility
and stability, and
the nature of the dosage form.
Pharmaceutical compositions suitable for the delivery of compounds of the
present
invention and methods for their preparation will be readily apparent to those
skilled in the
art. Such compositions and methods for their preparation may be found, for
example, in
'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company,
1995).
The compounds of the invention may be administered orally. Oral administration
may
involve swallowing, so that the compound enters tfe gastrointestinal tract, or
buccal or
sublingual administration may be employed by which the compound enters the
blood
stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such
as tablets,
capsules containing particulates, liquids, or powders, lozenges (including
liquid-filled),
chews, multi- and nano-particulates, gels, solid solution, liposome, films
(including muco-
adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs. Such
formulations
may be employed as fillers in soft or hard capsules and typically comprise a
carrier, for
example, water, ethanol, polyethylene glycol, propylene glycol,
methylcellulose, or a
suitable oil, and one or more emulsifying agents and/or suspending agents.
Liquid
formulations may also be prepared by the reconstitution of a solid, for
example, from a
sachet.
The compounds of the invention may also be used in fast-dissolving, fast-
disintegrating
dosage forms such as those described in Expert Opinion in Therapeutic Patents,
11 (6),
981-986 by Liang and Chen (2001).
For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to
80
wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage
form. In
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-25-
addition to the drug, tablets generally contain a disintegrant. Examples of
disintegrants
include sodium starch glycolate, sodium carboxymethyl cellulose, calcium
carboxymethyl
cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl
cellulose,
microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose,
starch,
pregelatinised starch and sodium alginate. Generally, the disintegrant will
comprise from 1
wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form.
Binders are generally used to impart cohesive qualities to a tablet
formulation. Suitable
binders include microcrystalline cellulose, gelatin, sugars, polyethylene
glycol, natural and
synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl
cellulose and
hydroxypropyl methylcellulose. Tablets may also contain diluents, such as
lactose
(monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol,
xylitol,
dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic
calcium
phosphate dihydrate.
Tablets may also optionally comprise surface active agents, such as sodium
lauryl sulfate
and polysorbate 80, and glidants such as silicon dioxide and talc. When
present, surface
active agents may comprise ' from 0.2 wt% to 5 wt% of the tablet, and glidants
may
comprise from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnesium stearate, calcium
stearate,
zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate
with sodium
lauryl sulphate. Lubricants generally comprise from 0.25 wt% to 10 wt%,
preferably from
0.5 wt% to 3 wt% of the tablet.
Other possible ingredients include anti-oxidants, colourants, flavouring
agents,
preservatives and taste-masking agents.
Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90
wt%
binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10
wt%
disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet
blends or
portions of blends may alternatively be wet-, dry-, or melt-granulated, melt
congealed, or
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-26-
extruded before tabletting. The final formulation may comprise one or more
layers and
may be coated or uncoated; it may even be encapsulated.
The formulation of tablets is discussed in "Pharmaceutical Dosage Forms:
Tablets, Vol.
1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-
8247-
6918-X).
Solid formulations for oral administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release.
Suitable modified release formulations for the purposes of the invention are
described in
US Patent No. 6,106,864. Details of other suitable release technologies such
as high
energy dispersions and osmotic and coated particles are to be found in Verma
et al,
Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum
to
achieve controlled release is described in WO 00/35298.
The compounds of the invention may also be administered directly into the
blood stream,
into muscle, or into an internal organ. Suitable means for parenteral
administration
include intravenous, intraarterial, intraperitoneal, intrathecal,
intraventricular, intraurehral,
intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices
for parenteral
administration include needle (including microneedle) injectors, needle-free
injectors and
infusion techniques.
Parenteral formulations are typically aqueous solutions which may contain
excipients such
as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to
9), but, for
some applications, they may be more suitably formulated as a sterile non-
aqueous
solution or as a dried form to be used in conjunction with a suitable vehicle
such as sterile,
pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for
example, by
lyophilisation, may readily be accomplished using standard pharmaceutical
techniques
well known to those skilled in the art.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-27-
The solubility of compounds of the present invention used in the preparation
of parenteral
solutions may be increased by the use of appropriate formulation techniques,
such as the
incorporation of solubility-enhancing agents.
Formulations for parenteral administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release. Thus compounds of the invention
may be
formulated as a solid, semi-solid, or thixotropic liquid for administration as
an implanted
depot providing modified release of the active compound. Examples of such
formulations
include drug-coated stents and PGLA microspheres.
The compounds of the invention may also be administered topically to the skin
or mucosa,
that is, dermally or transdermally. Typical formulations for this purpose
include gels,
hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings,
foams, films,
skin patches, wafers, implants, sponges, fibres, bandages and microemulsions.
Liposomes may also be used. Typical carriers include alcohol, water, mineral
oil, liquid
petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene
glycol.
Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88
(10),
955-958 by Finnin and Morgan (October 1999).
Other means of topical administration include delivery by electroporation,
iontophoresis,
phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM,
BiojectTM, etc.) injection.
Formulations for topical administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally or by
inhalation,
typically in the form of a dry powder (either alone, as a mixture, for
example, in a dry blend
with lactose, or as a mixed component particle, for example, mixed with
phospholipids,
such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray
from a
pressurised container, pump, spray, atomiser (preferably an atomiser using
electrohydrodynamics to produce a fine mist), or nebuliser, with or without
the use of a
suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-
heptafluoropropane.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-28-
For intranasal use, the powder may comprise a bioadhesive agent, for example,
chitosan
or cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser contains a
solution or
suspension of the compound(s) of the invention comprising, for example,
ethanol,
aqueous ethanol, or a suitable alternative agent for dispersing, solubilising,
or extending
release of the active, a propellant(s) as solvent and an optional surfactant,
such as
sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is
micronised to a
size suitable for delivery by inhalation (typically less than 5 microns). This
may be
achieved by any appropriate comminuting method, such as spiral jet milling,
fluid bed jet
milling, supercritical fluid processing to form nanoparticles, high pressure
homogenisation,
or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges
for use in an
inhaler or insufflator may be formulated to contain a powder mix of the
compound of the
invention, a suitable powder base such as lactose or starch and a performance
modifier
such as /-leucine, mannitol, or magnesium stearate. The lactose may be
anhydrous or in
the form of the monohydrate, preferably the latter. Other suitable excipients
include
dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomiser using
electrohydrodynamics to
produce a fine mist may contain from 1 pg to 20mg of the compound of the
invention per
actuation and the actuation volume may vary from 1 pl to 100pl. A typical
formulation may
comprise a compound of the invention, propylene glycol, sterile water, ethanol
and sodium
chloride. Alternative solvents which may be used instead of propylene glycol
include
glycerol and polyethylene glycol.
Suitable flavours, such as menthol and levomenthol, or sweeteners, such as
saccharin or
saccharin sodium, may be added to those formulations of the invention intended
for
inhaled/intranasal administration.
Formulations for inhaled/intranasal administration may be formulated to be
immediate
and/or modified release using, for example, poly(DL-lactic-coglycolic acid
(PGLA).
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-29-
Modified release formulations include delayed-, sustained-, pulsed-,
controlled-, targeted
and programmed release.
The compounds of the invention may be administered rectally or vaginally, for
example, in
the form of a suppository, pessary, or enema. Cocoa butter is a traditional
suppository
base, but various alternatives may be used as appropriate.
Formulations for rectal/vaginal administration may be formulated to be
immediate and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release.
The compounds of the invention may also be administered directly to the eye or
ear,
typically in the form of drops of a micronised suspension or solution in
isotonic, pH-
adjusted, sterile saline. Other formulations suitable for ocular and aural
administration
include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and
non-
biodegradable (e.g. silicone) implants, wafers, lenses and particulate or
vesicular
systems, such as niosomes or liposomes. A polymer such as crossed-linked
polyacrylic
acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example,
hyd roxypropyl methylcel I u lose, hyd roxyethylcel I u lose, or methyl
cellulose, or a
heteropolysaccharide polymer, for example, gelan gum, may be incorporated
together
with a preservative, such as benzalkonium chloride. Such formulations may also
be
delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted, or programmed release.
The compounds of the invention may be combined with soluble macromolecular
entities,
such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-
containing
polymers, in order to improve their solubility, dissolution rate, taste-
masking, bioavailability
and/or stability for use in any of the aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for
most
dosage forms and administration routes. Both inclusion and non-inclusion
complexes
may be used. As an alternative to direct complexation with the drug, the
cyclodextrin may
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-30-
be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser.
Most commonly
used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of
which
may be found in International Patent Applications Nos. WO 91/11172, WO
94/02518 and
WO 98/55148.
Inasmuch as it may desirable to administer a combination of active compounds,
for
example, for the purpose of treating a particular disease or condition, it is
within the scope
of the present invention that two or more pharmaceutical compositions, at
least one of
which contains a compound in accordance with the invention, may conveniently
be
combined in the form of a kit suitable for co-administration of the
compositions.
Thus the kit of the invention comprises two or more separate pharmaceutical
compositions, at least one of which contains a compound as hereinbefore
described in
accordance with the invention, and means for separately retaining said
compositions,
such as a container, divided bottle, or divided foil packet. An example of
such a kit is the
familiar blister pack used for the packaging of tablets, capsules and the
like.
The kit of the invention is particularly suitable for administering different
dosage forms, for
example, oral and parenteral, for administering the separate compositions at
different
dosage intervals, or for titrating the separate compositions against one
another. To assist
compliance, the kit typically comprises directions for administration and may
be provided
with a so-called memory aid.
For the avoidance of doubt, references herein to "treatment" include
references to
curative, palliative and prophylactic treatment.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-31-
CHEMISTRY EXAMPLES:
EXAMPLE 1:
(2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl
ester 2-methyl ester
O /
CI AN O
OX
--~
O 0
To a stirred solution of (2S, 4R)-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid
1-tert-
butyl ester 2-methyl ester (CAS Reg 74844-91-0) (6.lkg,24.87mo1), 3-
chlorophenol
(3.52kg,27.39mol) & triphenylphosphine (7.18kg,27.37mo1) in tert-butyl methyl
ether
(30.5L) at 0'C was added diisopropylazodicarboxylate (5.53kg,27.35mol) in tert-
butyl
methyl ether (15L) dropwise. The mixture was stirred overnight at 20'C. The
reaction was
filtered and the liquors washed with 0.5M sodium hydroxide (aq) (2 x 12.5L) &
water
(12.2L). The tert-butyl methyl ether solvent was replaced with n-heptane
(42.7L) by
atmospheric pressure distillation & cooled to crystallise crude product, which
was
collected by filtration (11.1 kg, 125% contaminated with ca 35% reduced
diisopropyl
dicarboxylate & triphenylphosphine oxide - corrected yield = 86%).
'H NMR (400MHz, CDCI3): 8 = 1.46, 1.49 (2 x s, 9H), 2.47 (2H, m), 3.71 (5H,
m), 4.42
(1 H, m), 4.42, 4.54 (1 H, 2 x m), 4.87 (1 H, m), 6.68 (1 H, m), 6.79 (1 H,
s), 6.92 (1 H, m),
7.18 (1 H, m).
LRMS (Electrospray): m/z 378 (MNa+).
(2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl
ester
CI 0
OH
O-~-'<
;"'/N-~
b,'O O
To (2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-
butyl
ester 2-methyl ester (11.1 kg, 20.28mo1) in THE (26.6L) was added a solution
of LiOH.H20
(4.86kg, 115.4mol) in water (55.5L). The mixture was stirred overnight at
25'C. The THE
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-32-
was removed by distillation & the resultant aqueous solution extracted with
dichloromethane (33.3L & 16.7L). The combined dichloromethane layers were
extracted
with water (33L & 16.7L). The combined aqueous phases were adjusted to pH 3-
3.5 with
1M hydrochloric acid(aq) & extracted with dichloromethane (2 x 22.2L). The
combined
dichloromethane phases were replaced with toluene (33.3L), which was cooled to
crystallise the product, which was collected by filtration (6.1 kg, 98%).
1H NMR (400 MHz, CDCI3): 3 = 1.42, 1.48 (2 x s, 9H), 2.30-2.70 (m, 2H), 3.60-
3.80 (m,
2H), 4.40-4.60 (m, 1 H), 4.86 (m, 1 H), 6.71 (m, 1 H), 6.82 (m, 1 H), 6.94 (m,
1 H), 7.16 (m,
1 H).
LRMS (Electrospray): m/z [MNa+] 364, 340 [M-1] 340.
(2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid (XXVIII)
CI 0
OH
NH
XXVIII
A solution of (2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid
1-tert-
butyl ester (29.25mo1) was dissolved in THE (20L) & filtered. To this solution
was added
4M HCI in dioxane (30L) & stirred overnight. Tert-Butyl methyl ether (70L) was
added to
the resultant suspension & the product was collected by filtration (7.06kg,
86.7%).
1H NMR (400 MHz, CD3OD): 6 = 2.65 (m, 2H), 3.60 (dd, 1 H), 3.70 (d, 1 H), 4.60
(dd, 1 H),
5.02 (m, 1 H), 6.88 (m, 1 H), 6.97 (s, 1 H), 7.03 (d, 1 H), 7.29 (dd, 1 H).
LRMS (Electrospray [MH+] 242, [M-1] 240.
Microanalysis: Found, C, 46.97; H, 4.70; N, 4.90. C11H12CIN03.HCIØ1H20
requires C,
47.20; H, 4.75; N, 5.00.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-33-
EXAMPLE 2:
4-(3-Fluoro-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2-
isopropyl-5-methyl-cyclohexyl) ester
O
ON
F
4-(3-Fluoro-benzylidene)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
2-(2-
isopropyl-5-methyl-cyclohexyl) ester (1.20 g, 2.61 mmol) was dissolved in
ethyl
acetate:toluene (1:1, 12 ml). The solution was submitted to hydrogenation on
platinum
oxide (120 mg, 10 % by weight) at 25 C and 15 psi for 1 hour. The reaction
mixture was
filtered through arbocel and the filtrate reduced under pressure. The residue
was purified
by flashmaster chromatography eluting with heptane:ethyl acetate (15:1) to
yield the title
compound as a colourless oil (1.11 g, 91 %).
'H-NMR (400MHz, CD3OD): 6 = 0.72-1.37 (m, 13 H), 1.44 (d, 9H), 1.43-1.75 (m,
4H),
1.87-2.01 (m, 2H), 2.31-2.58 (m, 2H), 2.83 (d, 2H), 3.07 (t, 1H), 3.50-3.65
(m, 1H), 4.13-
4.30 (dt, 1 H), 4.71 (td, 1 H), 6.90 (d, 2H), 7.00 (d, 1 H), 7.30 (q, 1 H).
LRMS (APCI): m/z [MH-BOC]+ 362.
(2S,4S)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid mono hydrochloride
salt (XXIX)
F
OH
i
NH
XXIX
4-(3-Fluoro-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2-
isopropyl-5-methyl-cyclohexyl) ester (0.91 g, 1.96 mmol) was dissolved in
toluene (2 ml).
6N hydrochloric acid (50m1) was added and stirred at reflux for 18 h. The
reaction mixture
was cooled to room temperature and extracted with ethyl acetate (3 x 20 ml).
The
aqueous layer was concentrated by evaporated under reduced pressure to give
the title
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-34-
compound (417mg, 81 %) as a white solid. 'H-NMR showed a 7:1 ratio of
cis:trans
diastereoisomers so the product was recrystallised from isopropyl alcohol to
give the title
compound (170mg, 65%) in a ratio of 14:1 cis:trans as determined by NMR.
'H-NMR (400MHz, CD3OD): (mixture of diastereoisomers 2S,4S:2S,4R (14:1)): b =
1.85
(q, 1H), 2.51 (quin, 1H), 2.69-2.85 (m, 3H), 3.07 (t, I H), 3.41 (dd, 1H),
4.38 and 4.48 (t,
1 H), 6.90-7.04 (m, 3H), 7.32 (q, 1 H).
LRMS (APCI): m/z [MH]+224.
[a]D25 -1.27 (c=9.00 in methanol).
Microanalysis: Found C, 55.56; H, 5.81; N, 5.34%. C12H14FN02.HCI requires C,
55.50; H,
5.82; N, 5.39%.
EXAMPLE 3:
4-(3-Fluoro-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2-
isopropyl-5-methyl-cyclohexyl) ester
0-11,
0"-k'
"'N
O / \
F
O
F
4-(3-Fluoro-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2-
isopropyl-5-methyl-cyclohexyl) ester was prepared by a method analogous to
that for the
preparation of 4-(3-Fluoro-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-
butyl ester 2-(2-
isopropyl-5-methyl-cyclohexyl) ester, using the appropriate starting alkenic
menthol ester;
[MH]480
Microanalysis (mixture of diastereoisomers cis (major) and trans): Found: C,
67.74; H,
8.30; N, 2.90%. C27H39 F2NO4. requires C, 67.62; H, 8.20; N, 2.92%;
[a]D25 -71.92 (c = 3.26 in methanol)
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-35-
(2S,4S)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid mono-
hydrochloride salt (XXX)
F
OH
cJ NH
XXX
The title compound was made by the method of example 2, starting from 4-(3-
Fluoro-
benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2-isopropyl-5-
methyl-
cyclohexyl) ester, and purified by re-crystallisation with acetone/ether to
give the title
compound as a mixture of diastereoisomers (2S,4S:2S,4R (12:1)) determined by
'H-NMR
(500 mg, 60 %) as a white solid.
1H-NMR (400 MHz, CD3OD) (mixture of diastereoisomers cis :trans (12:1)): 6=
0.80-1.90
(m, 0.92H), 2.12-2.20 (m, 0.08H), 2.28-2.36 (m, 0.08H), 2.49-2.58 (q, 0.92H),
2.66-2.81
(m, 1H), 2.83-2.95 (m, 2H), 3.02-3.13 (t, 1H), 3.46 (dd, 1H), 4.40 (dd,
0.92H), 4.48-4.54
(m, 0.08H), 7.03-7.20 (m, 3H).
LRMS (Electrospray): m/z [M + H]+ 242.
Microanalysis: Found C, 51.42; H, 5.08; N, 5.01%. C12H13NO2F2.HCI requires C,
51.90; H,
5.08; N, 5.04%.
EXAMPLE 4:
(2S,4S)-Pyrrolidins-1,2,4-tricarboxylic acid 1,2-di-tert-butyl ester
OH
0
O
O~
O O
To a mixture of 4-phenyl-pyrrolidine-1,2-dicarboxylic acid di-tert-butyl ester
(CAS
Reg. No. 344 286-69-7; J. Org. Chem., 2001, 3593-3596) (0.78g, 2.24mmol) and
sodium
periodate (5.77g, 27mmol) stirring at 0 C under a nitrogen atmosphere in ethyl
acetate
(5.5m1), acetonitrile (5.5m1) and water (8.5m1) was added ruthenium
trichloride (10mg,
0.05mmol) and stirred to room temperature over 18 hours. Diethyl ether (20ml)
was added
and stirred for a further 1 hr. 1 M hydrochloric acid (5m1) was added and the
mixture
extracted with ethyl acetate (3 x 30m1). Organic extracts were combined, dried
(MgSO4),
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-36-
filtered and evaporated under reduced pressure. The residue was purified by
chromatography on silica gel, eluting with 50:50:1 ethyl
acetate:heptane:glacial acetic acid
to give the title compound as a colourless gum (501 mg, 78%)
'H-NMR (400MHz, CDCI3): 6 = 1.40-1.49 (m, 18H); 2.26-2.40 (m, 1 H); 2.42-2.56
(m, 1 H);
3.02-3.12 (m, 1 H); 3.65-3.80 (m, 1.4H) & 3.80-3.88 (m, 0.6H) [rotamers]; 4.09-
4.20 (m,
0.7H) & 4.20-4.26 (m, 0.3H) [rotamers]
LRMS (electrospray): [M-1] 314
(2S,4S)-4-(3-fluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid (XXI)
O OH
F _q NH
O
XXI
4-(3-fluoro-phenoxymethyl)-pyrroline-1,2-dicarboxylic acid di-tert-butyl ester
(475mg, 1.2mmol) was dissolved in a solution of anhydrous hydrogen chloride in
dioxane
(4M, 15ml) and stirred at 50 C under a nitrogen atmosphere for 1 hour. The
solvent was
removed under reduced pressure and the resulting semi-solid triturated with
ethyl acetate
to give a white solid which was recrystallised from ethyl acetate/isopropyl
alcohol to give
the title compound as a mixture of diastereomers (-5:1 2S,4S:2S,4R) as a white
solid
hydrochloride salt (90mg, 35%)
'H-NMR (400MHz, CD3OD): 6 = 2.04-2.09 (m, 0.8H); 2.33-2.47 (m, 0.4H); 2.65-
2.75 (m,
0.8H); 2.88-3.00 (m, 1H); 3.33-3.40 (m, 1H); 3.52-3.60 (m, 0.8H); 3.60-3.68
(0.2H); 3.96-
4.04 (m, 1H); 4.04-4.12 (m, 1H); 4.42-4.51 (m, 0.8H); 4.40-4.56 (m, 0.2H);
6.65-6.80 (m,
3H), 7.21-7.30 (m, 1H)
LRMS (electrospray): [M+1] 240; [M+23] 262; [M-1] 238.
EXAMPLE 5:
(3S,5R)-3-Amino-5-methyl-octanoic acid hydrochloride(R)-2,6-Dimethyl-non-2-
ene.
To (S)-citronellyl bromide (50 g, 0.228 mol) in THE (800 mL) at 0 C was added
LiCI (4.3 g)
followed by CuCl2 (6.8 g). After 30 minutes methylmagnesium chloride (152 mL
of a 3 M
solution in THF, Aldrich) was added and the solution warmed to room
temperature. After
hours the solution was cooled to 0 C and a saturated aqueous solution of
ammonium
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-37-
chloride carefully added. The resultant two layers were separated and the
aqueous phase
extracted with ether. The combined organic phases were dried (MgSO4) and
concentrated to give (R)-2,6-dimethyl-non-2-ene. 32.6 g; 93%. Used without
further
purification. 1H NMR (400 MHz; CDCI3) 6 5.1 (m, 1 H), 1.95 (m, 2H), 1.62 (s,
3H), 1.6 (s,
3H), 1.3 (m, 4H), 1.2 (m, 2H), 0.8 (s, 6H).
(R)-4-Methyl-heptanoic acid.
To (R)-2,6-dimethyl-non-2-ene (20 g, 0.13 mol) in acetone (433 mL) was added a
solution
of Cr03 (39 g, 0.39 mol) in H2SO4 (33 mL)/H20 (146 mL) over 50 minutes. After
6 hours
a further amount of Cr03 (26 g, 0.26 mol) in H2SO4 (22 mL)/H20 (100 ml-) was
added.
After 12 hours the solution was diluted with brine and the solution extracted
with ether.
The combined organic phases were dried (MgSO4) and concentrated. Flash
chromatography (gradient of 6:1 to 2:1 hexane/EtOAc) gave (R)-4-methyl-
heptanoic acid
as an oil. 12.1 g; 65%. MS, m/z (relative intensity): 143 [M-H, 100%].
(4R, 5S)-4-Methyl-3-((R)-4-methyl-heptanoyl)-5-phenyl-oxazolidin-2-one.
To (R)-4-methyl-heptanoic acid (19 g, 0.132 mol) and triethylamine (49.9 g,
0.494 mol) in
THE (500 mL) at 0 C was added trimethylacetylchloride (20 g, 0.17 mol). After
1 hour LiCl
(7.1 g, 0.17 mol) was added foliowed by (4R,5S)-(+)-4-methyl-5-phenyl-2-
oxazolidinone) 3
(30 g, 0.17 mol). The mixture was warmed to room temperature and after 16
hours the
filtrate was removed by filtration and the solution concentrated under reduced
pressure.
Flash chromatography (7:1 hexane/EtOAc) gave (4R,5S)-4-methyl-3-((R)-4-methyl-
heptanoyl)-5-phenyl-oxazolidin-2-one as an oil. 31.5 g; 79%. [a]D = +5.5 (c 1
in CHCI3).
MS, m/z (relative intensity): 304 [M+H, 100%].
(3S, 5R)-5-Methyl-3-((4R, 5S)-4-methyl-2-oxo-5-phenyl-oxazoi idi ne-3-
carbonyl)-
octanoic acid tert-butyl ester.
To (4R,5S)-4-methyl-3-((R)-4-methyl-heptanoyl)-5-phenyl-oxazolidin-2-one (12.1
g,
0.04 mol) in THE (200 ml) at -50 C was added sodium bis(trimethylsilyl)amide
(48 mL of a
1 M solution in THF). After 30 min t-butylbromoaceate (15.6 g, 0.08 mol) was
added. The
solution was stirred for 4 hours at -50 C and then warmed to room temperature.
After
16 hours a saturated aqueous solution of ammonium chloride was added and the
two
layers separated. The aqueous phase was extracted with ether and the combined
organic
phases dried (MgSO4) and concentrated. Flash chromatography (9:1 hexane/EtOAc)
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-38-
gave (3S,5R)-5-methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidine-3-
carbonyl)-
octanoic acid tert-butyl ester as a white solid 12 g; 72%. [a]D = +30.2 (c 1
in CHCI3). 13C
NMR (100 MHz; CDCI3) i5 176.47, 171.24, 152.72, 133.63, 128.87, 125.86, 80.85,
78.88,
55.34, 39.98, 38.77, 38.15, 37.58, 30.60, 28.23, 20.38, 20.13, 14.50, 14.28.
(S)-2-((R)-2-Methyl-pentyl)-succinic acid 4-tert-butyl ester.
To (3S,5R)-5-methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidine-3-carbonyl)-
octanoic acid tert-butyl ester (10.8 g, 0.025 mol) in H2O (73 mL) and THE (244
mL) at 0 C
was added a premixed solution of LiOH (51.2 mL of a 0.8 M solution) and H202
(14.6 mL
of a 30% solution). After 4 hours a further 12.8 mL LiOH (0.8 M solution) and
3.65 mL of
H202 (30% solution) was added. After 30 minutes sodium bisulfite (7 g), sodium
sulfite
(13 g), and water (60 mL) was added followed by hexane (100 mL) and ether (100
mL).
The two layers were separated and the aqueous layer extracted with ether. The
combined
organic phases were concentrated to an oil that was dissolved in heptane (300
mL). The
resultant solid was filtered off and the filtrate dried (MgSO4) and
concentrated to afford
(S)-2-((R)-2-methyl-pentyl)-succinic acid 4-tert--butyl ester (6 g, 93%) which
was used
immediately without further purification. MS, m/z (relative intensity): 257
[M+H, 100%].
(3S, 5R)-3-Benzyoxycarbonylamino-5-methyl-octanoic agid, tent-butyl ester.
A solution of (S)-2-((R)-2-methyl-pentyl)-succinic acid 4-tert-butyl ester
(6.0 g, 23.22
mmol) and triethylamine (3.64 mL, 26.19 mmol) in toluene (200 mL) was treated
with
diphenylphosphoryl azide (5.0 mL, 23.22 mL) and stirred at room temperature
for 0.5
hours. After the reaction mixture was then heated at reflux for 3h and cooled
briefly,
benzyl alcohol was added (7.2 mL, 69.7 mmol) and the solution heated for
another 3 h.
After the reaction mixture was allowed to cool, it was diluted with ethyl
ether (200 mL) and
the combined organic layer was washed successively with saturated NaHCO3 and
brine
and dried (Na2SO4). The concentrated organic component was purified by
chromatography (MPLC) eluting with 8:1 hexanes: ethyl acetate to provide (3S,
5R)-3-
benzyoxycarbonylamino-5-methyl-octanoic acid, tert-butyl ester (6.4 g, 75.8%).
MS: M+1:
364.2, 308.2.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-39-
(3S, 5R)-3-Amino-5-methyl-octanoic acid, tert-butyl ester.
A solution of (3S, 5R)-3-benzyoxycarbonylamino-5-methyl-octanoic acid, tert-
butyl ester
(2.14g, 5.88 mmol) in THE (50 ml-) was treated with Pd/C (0.2 g) and H2 at 50
psi for 2
hours. The reaction mixture was then filtered and concentrated to an oil in
vacuo to give
(3S, 5R)-3-amino-5-methyl-octanoic acid, tert-butyl ester in quantitative
yield. MS: M+1:
230.2, 174.1.
(3S, 5R)-3-Amino-5-methyl-octanoic acid hydrochloride.
A slurry of (3S, 5R)-amino-5-methyl-octanoic acid, tent-butyl ester (2.59g,
11.3 mmol) in
6N HCI (100 mL) was heated under reflux 18 hours, cooled, and filtered over
Celite. The
filtrate was concentrated in vacuo to 25 mL and the resulting crystals were
collected and
dried to provide (3S, 5R)-3-amino-5-methyl-octanoic acid hydrochloride, mp
142.5-
142.7 C (1.2g, 50.56%). A second crop (0.91g) was obtained from the filtrate.
Anal.
Calc'd for CgH,9NO2-HCI: C: 51.55, H: 9.61, N: 6.68, Cl: 16.91. Found: C:
51.69, H: 9.72,
N: 6.56, Cl: 16.63.
(3S, 5R)-3-Amino-5-methyl-octanoic acid hydrochloride acid salt.
5.3 g of 2S-(2R-methyl-pentyl)-succinic acid-4-tert-butyl ester contained in
30 mL
methyltertbutyl ether is reacted at room temperature with 3.5 mL triethylamine
followed by
6.4 g of diphenylphosphoryl azide. After allowing the reaction to exotherm to
45 C and
stirring for at least 4 hours, the reaction mixture is allowed to cool to room
temperature
and stand while the phases separated. The lower layer is discarded and the
upper layer
is washed with water, followed by dilute aqueous HCI. The upper layer is then
combined
with 10 mL of 6 N aqueous HCI, and stirred at 45-65 C. The reaction mixture is
concentrated by vacuum distillation to about 10 -14 mL and allowed to
crystallize while
cooling to about 5 C. After collecting the product by filtration, the product
is washed with
toluene and reslurried in toluene. The product is dried by heating under
vacuum resulting
in 2.9 g (67%) of white crystalline product. The product may be recrystallized
from
aqueous HCI. mp 137 C.
EXAMPLE 6:
Methanesulfonic acid (S)-3,7-dimethyl-oct-6-enyl ester.
To S-(-)-citronellol (42.8 g, 0.274 mol) and triethylamine (91 mL, 0.657 mol)
in CH2CI2
(800 ml-) at 0 C was added methanesulphonyl chloride (26 mL, 0.329 mol) in
CH2CI2
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-40-
(200 mL). After 2 hours at 0 C the solution was washed with 1 N HCI then
brine. The
organic phase was dried (MgSO4) and concentrated to afford the titled compound
an oil
(60.5 g, 94%) which was used without further purification. MS, m/z (relative
intensity): 139
[100%], 143 [100%].
(R)-2,6-Dimethyl-oct-2-ene.
To methanesulfonic acid (S)-3,7-dimethyl-oct-6-enyl ester (60 g, 0.256 mol) in
THE (1 L)
at 0 C was added lithium aluminium hydride (3.8 g, 0.128 mol). After 7 hours,
a further
3.8 g of lithium aluminum hydride was added and the solution warmed to room
temperature. After 18 hours, a further 3.8 g of lithium aluminum hydride was
added. After
a further 21 hours, the reaction was carefully quenched with 1 N citric acid
and the solution
diluted further with brine. The resultant two phases were separated and the
organic phase
was dried (MgSO4) and concentrated to afford the titled compound as an oil
which was
used without further purification. MS, m/z (relative intensity): 139 [M+H,
100%].
(R)-4-Methyl-hexanoic acid.
A procedure similar to the synthesis of (R)-4-methyl-heptanoic acid was
utilized giving the
acid as an oil (9.3 g, 56%). MS, m/z (relative intensity): 129 [M-H, 100%].
(4R,5S)-4-Methyl-3-((R)-4-methyl-hexanoyl)-5-phenyl-oxazolidin-2-one.
A procedure similar to the synthesis of (4R,5S)-4-methyl-3-((R)-4-methyl-
heptanoyl)-5-
phenyl-oxazolidin-2-one was utilized giving the titled compound as an oil
(35.7 g, 95%).
MS, m/z (relative intensity): 290 [M+H, 100.
(3S,5R)-5-Methyl-3-[1-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-yl)-
methanoyl]-
heptanoic acid tert-butyl ester.
A procedure similar to the preparation of (3S,5R)-5-methyl-3-((4R,5S)-4-methyl-
2-oxo-5-
phenyl-oxazolidine-3-carbonyl)-octanoic acid tert-butyl ester was followed
giving the titled
compound as an oil (7.48 g; 31 %). MS, m/z (relative intensity): 178 [100%],
169 [100%];
[a]D = + 21.6 (c 1 in CHCI3).
(S)-2-((R)-2-Methyl-butyl)-succinic acid 4-tert-butyl ester.
(3S,5R)-5-Methyl-3-[1-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-yl)-
methanoyl]-
heptanoic acid tert-butyl ester (7.26 g, 0.018 mol) in H2O (53 mL) and THE
(176 mL) at
0 C was added a premixed solution of LiOH (37 mL of a 0.8 M solution) and H202
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-41-
(10.57 mL of a 30% solution) and the solution warmed to room temperature.
After 2 hours
sodium bisulfite (7 g), sodium sulfite (13 g), and water (60 mL) was added and
the two
layers were separated and the aqueous layer extracted with ether. The combined
organic
phases were concentrated to an oil that was dissolved in heptane (200 mL). The
resultant
solid was filtered off and the filtrate dried (MgSO4) and concentrated to
afford the titled
compound as an oil (4.4 g) that was used without further purification. MS, m/z
(relative
intensity): 243 [100%].
(3S, 5R)-3-Benzyoxycarbonylamino-5-methyl-heptanoic acid, tert-butyl ester.
This compound was prepared as described above starting with (S)-2-((R)-2-
methyl-butyl)
succinic acid, 4-tert-butyl ester to give (3S, 5R)-3-benzyoxycarbonylamino-5-
methyl-
heptanoic acid, tert-butyl ester as an oil (73.3% yield). 1H NMR (400 MHz;
CDCI3) 8
0.84(t, 3H, J = 7.33 Hz), 0.89(d, 3H, J = 6.60 Hz), 1.12-1.38 (m, 4H), 1.41
(s, 9H), 1.43-
1.59 (m, 2H), 2.42 (m, 2H), 4.05 (m, 1 H), 5.07 (t, 2H J =12.95 Hz), and 7.28-
7.34 (m, 5H).
(3S, 5R)-Amino-5-methyl-heptanoic acid, tert-butyl ester
This compound was prepared as described above starting with (3S, 5R)-3-
benzyoxycarbonylamino-5-methyl-heptanoic acid, tert-butyl ester instead of
(3S, 5R)-3-
benzyoxycarbonylamino-5-methyl-octanoic acid, tert-butyl ester to give the
titled
compound. 'H NMR (400 MHz; CDCI3) 8 0.84 (overlapping t and d, 6H), 1.08-
1.16(m,
2H), 1.27-1.30(m, 2H), 1.42(s, 9H), 1.62 (br s, 2H), 2.15 (dd, 1 H, J= 8.54
and 15.62 Hz),
2.29(dd, 1 H, J = 4.15 and 15.37 Hz), and 3.20(br s, 2H).
(3S, 5R)-Amino-5-methyl-heptanoic acid hydrochloride
A slurry of (3S, 5R)-amino-5-methyl-heptanoic acid, tent-butyl ester (1.44g,
6.69 mmol) in
3N HCI was heated at reflux for 3 hours, filtered hot over Celite, and
concentrated to
dryness. Trituration of the resulting solid in ethyl ether provided (3S, 5R)-3-
amino-5-
methyl-heptanoic acid hydrochloride, (0.95g, 85%) mp 126.3-128.3 C.
EXAMPLE 7:
(3S, 5R)-3-Amino-5-methyl-nonanoic acid
(R)-4-Methyl-octanoic acid. Lithium chloride (0.39 g, 9.12 mmol) and copper
(I) chloride
(0.61 g, 4.56 mmol) were combined in 45 ml THE at ambient temperature and
stirred
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-42-
15 minutes, then cooled to 0 C at which time ethylmagnesium bromide (1 M
solution in
THF, 45 mL, 45 mmol) was added. (S)-citronellyl bromide (5.0 g, 22.8 mmol) was
added
dropwise and the solution was allowed to warm slowly to ambient temperature
with stirring
overnight. The reaction was quenched by cautious addition of sat. NH4CI (aq),
and stirred
with Et20 and sat. NH4CI (aq) for 30 minutes. The phases were separated and
the
organic phase dried (MgSO4) and concentrated. The crude (R)-2,6-dimethyl-dec-2-
ene
was used without purification. To a solution of (R)-2,6-dimethyl-dec-2-ene
(3.8 g, 22.8
mmol) in 50 mL acetone at 0 C was added Jones' reagent (2.7 M in H2SO4 (aq),
40 mL,
108 mmol) and the solution was allowed to warm slowly to ambient temperature
with
stirring overnight. The mixture was partitioned between Et20 and H20, the
phases were
separated, and the organic phase washed with brine, dried (MgS04), and
concentrated.
The residue was purified by flash chromatography (8:1 hexanes:EtOAc) to afford
2.14 g
(59%) of the titled compound as a colourless oil: LRMS: m/z 156.9 (M+). Jones'
reagent
.i.
was prepared as a 2.7M solution by combining 26.7g Cr03, 23 mL H2SO4, and
diluting to
100 mL with H20.
(4R, 5S)-4-Methyl-3-((R)-4-methyl-octanoyl)-5-phenyl-oxazolidin-2-one.
To (R)-4-methyl-octanoic acid (2.14 g, 13.5 mmol) in 25 mL CH2CI2 at 0 C was
added
3 drops DMF, followed by oxalyl chloride (1.42 mL, 16.2 mmol) resulting in
vigorous gas
evolution. The solution was warmed directly to ambient temperature, stirred 30
minutes,
and concentrated. Meanwhile, to a solution of the oxazolidinone (2.64 g, 14.9
mmol) in 40
mL THE at -78 C was added n-butyllithium (1.6 M soln in hexanes, 9.3 mL, 14.9
mmol)
dropwise. The mixture was stirred for 10 minutes at which time the acid
chloride in 10 mL
THE was added dropwise. The reaction was stirred 30 minutes at -78 C, then
warmed
directly to ambient temperature and quenched with sat. NH4CI. The mixture was
partitioned between Et2O and sat. NH4CI (aq), the phases were separated, and
the
organic phase dried (MgS04), and concentrated to furnish 3.2 g of the titled
compound as
a colourless oil. LRMS: m/z 318.2 (M+).
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
- 43 -
(3S,5R)-5-Methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazo I idi ne-3-carbonyl)-
nonanoic acid tert-butyl ester.
To a solution of diisopropylamine (1.8 mL, 12.6 mmol) in 30 mL THE at -78 C
was added
n-butyllithium (1.6 M soln in hexanes, 7.6 mL, 12.1 mmol), and the mixture
stirred
minutes at which time (4R, 5S)-4-Methyl-3-((R)-4-methyl-octanoyl)-5-phenyl-
oxazolidin-2-one (3.2 g, 10.1 mmol) in 10 mL THE was added dropwise. The
solution was
stirred for 30 minutes, t-butyl bromoacetate (1.8 mL, 12.1 mmol) was added
quickly
dropwise at -50 C, and the mixture was allowed to warm slowly to 10 C over 3
hours. The
mixture was partitioned between Et2O and sat. NH4CI (aq), the phases were
separated,
and the organic phase dried (MgSO4), and concentrated. The residue was
purified by
flash chromatography (16:1 to 8:1 hexanes:EtOAc) to provide 2.65 g (61%) of
the titled
compound as a colourless crystalline solid, mp = 84-86 C. [61D 23 +17.1 (c =
1.00,
CHCI3).
(S)-2-((R)-2-Methyl-hexyl)-succinic acid 4-tert-butyl ester.
To a solution of (3S,5R)-5-Methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyl-
oxazolidine-3-
carbonyl)-nonanoic acid tert-butyl ester (2.65 g, 6.14 mmol) in 20 mL THE at 0
C was
added a precooled (0 C) solution of LiOH monohydrate (1.0 g, 23.8 mmol) and
hydrogen
peroxide (30 wt% aqueous soln, 5.0 mL) in 10 mL H2O. The mixture was stirred
vigorously for 90 minutes, then warmed to ambient temperature and stirred 90
minutes.
The reaction was quenched at 0 C by addition of 100 mL 10% NaHSO3 (aq), then
extracted with Et20. The phases were separated, and the organic phase washed
with
brine, dried (MgSO4), and concentrated. The titled compound was used without
purification.
(3S, 5R)-3-Benzyoxycarbonylamino-5-methylnonanoic acid, tert-butyl ester
This compound was prepared similarly as described above starting with (S)-2-
((R)-2-
methylhexyl) succinic acid, 4-tert-butyl ester instead of (S)-2-((R)-2-
methylpentyl) succinic
acid, 4-tert-butyl ester to provide the titled compound as an oil (71.6%
yield). 1HNMR (400
MHz; CDCI3) 8 0.81(t, 3H, J = 4.40 Hz), 0.85(d, 3H, J = 6.55 Hz), 1.06-1.20(m,
7H),
1.36(s, 9H), 1.38-1.50(m, 2H), 2.36(m, 2H), 3.99(m, 1H), 5.02(m+s, 3H), and
7.28-7.28(m,
5H).
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-44-
(3S, 5R)-3-Amino-5-methyl-nonanoic acid, tert-butyl ester
This compound was prepared as described above starting with (3S, 5R)-
benzyoxycarbonylamino-5-methyl-nonanoic acid, tert-butyl ester instead of (3S,
5R)-3-
benzyoxycarbonylamino-5-methyl-octanoic acid, tert-butyl ester. Yield = 97%.
'HNMR
(400 MHz; CDCI3) S 0.82(overlapping d and t, 6H), 1.02-1.08(m, 1 H), 1.09-
1.36(m, 6H),
1.39(s, 9H), 1.47(br s, 1 H), 1.80(s, 2H), 2.13(dd, 1 H, J = 8.54 and 15.61
Hz), and 2.27(dd,
1 H, J = 4.15 and 15.38 Hz).
(3S, 5R)-3-Amino-5-methyl-nonanoic acid hydrochloride
A mixture of (3S, 5R)-3-amino-5-methyl-nonanoic acid, tert-butyl ester (1.50g,
6.16 mmol)
in 3N HCI (100 ml-) was heated at reflux for 3hours, filtered hot over Celite,
and
concentrated to 30mL in vacuo. The resulting crystals were collected, washed
with
additional 3N HCl, and dried to provide the title compound, mp 142.5-143.3 C.
Additional
crops were obtained from the filtrate to provide 1.03g (70.4%). Anal. Calc'd
for
C10H21NO2-HCI: C: 53.68, H: 9.91, N: 6.26, Cl: 15.85. Found: C: 53.89, H:
10.11, N: 6.13.
MS: M+1: 188.1.
BIOLOGY EXAMPLES:
The biological activity of compounds suitable for use in the invention as
alpha-2-delta
ligands may be measured in a radioligand binding assay using [3H]gabapentin
and the a-
2-S subunit derived from porcine brain tissues (Gee N.S., Brown J.P.,
Dissanayake
V.U.K., Offord J., Thurlow R., Woodruff G.N., J. Biol. Chem., 1996;271:5879-
5776).
Example 1: Investigation into the effects of an alpha-2-delta ligand on the
micturition reflex of anaesthetised rats.
1.0 Material and methods:
Animals
Four caesarean derived (CD) rats weighing approximately 225 g were
anaesthetised
using urethane and continuous cystometry performed.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-45-
The animals were anaesthetised using urethane (1.2 g/kg, i.p.). Depth of
anaesthesia
was assessed by the stability of blood pressure and heart rate, and by an
absence of hind
limb withdrawal in response to paw pinch. Supplementary doses of urethane (0.1
g kg-1,
i.v.) were given where necessary.
The trachea was intubated to maintain a patent airway, an external jugular
vein was
cannulated for drug administration, and a common carotid artery was cannulated
with a
heparinised cannula (20 units/ml heparin in 0.9% w/v saline) for the
measurement of
arterial blood pressure.
Blood pressure was measured using a pressure transducer and the heart rate
(HR)
derived electronically on-line from the blood pressure using PoneMah (Linton
Pty Ltd UK).
Body temperature was monitored with a rectal temperature probe and maintained
between 36 - 38 C using a homeothermic blanket system (Harvard, UK). Animals
were
allowed to breathe air spontaneously throughout the duration of the
experiment.
The urinary bladder was exposed by a midline abdominal incision. A cannula (c.
0.52 mm
internal and 1.2 mm external diameter) was inserted into the bladder dome as a
means of
infusing the bladder while simultaneously recording intravesical bladder
pressure. The
bladder was infused with physiological saline (0.9%) at the rate of 0.046
ml/min, to
simulate the maximal hourly diuresis rate of the rat (Klevmark B [1974] -
Motility of the
urinary bladder in cats during filling at physiological rates. I. Intravesical
pressure patterns
studied by a new method of cystometry. Acta Physiol Scand 90(3): 565-77).
Following the surgical procedure the animals were allowed to stabilise for
c. 30min. After the stabilisation period, cystometry was performed and bladder
function
(interval between micturition) in response to Gabapentin-HCI (0.3, 1, 3 and 10
mg/kg
administered intravenously) was monitored.
Statistical analysis
Differences between treatment groups were examined using ANOVA.
Compound
Gabapentin-HCI (Tocris, UK) was dissolved in saline.
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-46-
2.0 Results:
Time interval between voiding episodes
The interval between voiding events was increased in response to gabapentin
(see Fig 1)
relative to corresponding control periods. It was observed from the study that
gabapentin
significantly extended the interval between voiding events in a dose dependent
manner.
Indeed, 10 mg/kg of gabapentin administered intravenously significantly
prolonged the
micturition interval relative to corresponding control animals (3.1 0.29 v
9.89 2.72 min
P<0.05). As a consequence of improving the interval between micturition events
bladder
capacity was improved significantly by 200% in response to gabapentin. It is
interesting to
note that gabapentin, when administered at 10 mg/kg, did not have any adverse
effects on
micturition efficiency, urine retention or bladder contraction upon voiding.
Thus it is demonstrated that administration of an alpha-2-delta ligand
increases bladder
capacity and reduces the LUTS in female animals, indicating the utility of
such an
approach in treating the LUTS associated with OAB.
Example 2: Effect of an alpha-2-delta ligand on micturition frequency and
bladder
pressure in the male spontaneously hypertensive rat (SHR).
1.0 Materials and Methods:
Eight (8) male spontaneously hypertensive rats were prepared surgically with
Data
Sciences International (DSI) telemetry transponders (TL11 M2-C50-PXT). Bladder
pressure was continuously monitored with the aid of a pressure catheter placed
via the
dome of the bladder.
Bladder parameters (bladder pressure, voiding pressure and the number of
voids) were
recorded in response to placebo or treatment with 60 mg/kg Gabapentin
administered
subcutaneously (s/c).
CA 02509605 2005-06-10
WO 2004/054560 PCT/IB2003/005729
-47-
2.0 Results:
As depicted in Figure 2, Gabapentin at 60 mg/kg s/c significantly decreased
(P<0.05)
micturition interval and hence increased bladder capacity. Moreover, and
importantly for
lower urinary tract symptoms (LOTS), average bladder pressure during the
filling stages of
the micturition cycle were significantly decreased (P<0.05) in response to
Gabapentin
relative to corresponding control periods (see Figure 3).
Thus it is demonstrated that administration of an alpha-2-delta ligand
increases bladder
capacity and reduces the LUTS in male animals, indicating the utility of such
an approach
in treating the LUTS associated with BPH.
